Inhaler testing equipment company Copley Scientific will more than double the size of its headquarters in Colwick, Nottingham, UK, the company has announced. Construction on the new building is expected to be complete by the end of 2017. The new facility will include additional manufacturing and warehousing space, as well as meeting and training rooms. Copley … [Read more...] about Copley Scientific to expand headquarters
News
Spyryx Biosciences announces positive results from Phase 1 study of SPX-101
According to Spyryx Biosciences, a Phase 1 study of its SPX-101, an inhaled SPLUNC1-derived peptide that the company is developing for the treatment of cystic fibrosis, showed that the drug was well tolerated, with no reduction in lung function and no dose-limiting adverse effects. Based on those results, the company is planning a Phase 2 study in CF patients. The … [Read more...] about Spyryx Biosciences announces positive results from Phase 1 study of SPX-101
Oxford Lasers patent case win will allow marketing of EnVision spray characterization system in Europe
Oxford Lasers has announced that it will be able to supply its EnVision spray characterization system in Europe following a decision in its favor by the European Patent Office Board of Appeal. The decision revoked European patent 1210580, based on US patent 6,785,400, "Spray Data Acquisition Method," which belongs to Proveris Scientifc. US patent 6,785,400, which … [Read more...] about Oxford Lasers patent case win will allow marketing of EnVision spray characterization system in Europe
MannKind launches Afrezza titration pack, expands sales force
MannKind Corporation has announced the availability of a new titration pack which includes 60 each of 4, 8, and 12 unit cartridges of Afrezza inhalation powder. The company already offers a titration pack that includes 90 each of 4 and 8 unit cartridges, which it says accounts for nearly 25% of Afrezza units dispensed on a weekly basis. According to the company, … [Read more...] about MannKind launches Afrezza titration pack, expands sales force
Promising data from preclinical study of intranasal therapy for optic neuritis
Noveome Biotherapeutics has announced the publication of promising data from a preclinical study of its ST266 intranasal secretome showing anti-inflammatory activity and retinal ganglion cell (RGC) retention in the optic nerve in a mouse multiple sclerosis model. The article, titled, “Intranasal Delivery of a Novel Amnion Cell Secretome Prevents Neuronal Damage and … [Read more...] about Promising data from preclinical study of intranasal therapy for optic neuritis
FDA accepts OptiNose NDA for OPN-375 intranasal fluticasone
The FDA has accepted OptiNose’s new drug application for its OPN-375 intranasal fluticasone for the treatment of nasal polyposis in adult patients, with an anticipated PDUFA date in September 2017, the company announced. OptiNose CEO Peter Miller commented, “The FDA acceptance of the new drug application for OPN-375 is a particularly exciting milestone for our … [Read more...] about FDA accepts OptiNose NDA for OPN-375 intranasal fluticasone
Extrafine particles and the potential for enhanced inhaled drug delivery: A Q&A with Chiesi’s Dave Lewis
Q: What benefits are offered by extrafine particles? A: There is growing evidence to suggest that finer aerosols may enable us to effectively direct particles into more efficacious areas of the lung and to achieve a more uniform localized response. Furthermore, data we presented at RDD 2016 demonstrate that finer particles could deliver performance that is more … [Read more...] about Extrafine particles and the potential for enhanced inhaled drug delivery: A Q&A with Chiesi’s Dave Lewis
Beximco joint venture with BioCare includes new GMP inhaler facility
Bangladeshi generics company Beximco Pharmaceuticals announced that it has entered into a joint venture with Malaysian pharma company BioCare and said that the first joint project, an MDI manufacturing facility in Seri Iskandar Pharmaceutical Park, Perak, Malaysia, has already received GMP approval from the Malaysian Ministry of Health. Beximco, which will own 30% … [Read more...] about Beximco joint venture with BioCare includes new GMP inhaler facility
Pulmatrix announces $5 million registered direct offering
Inhaled drug developer Pulmatrix has announced an agreement to sell approximately 2 million shares of its common stock to institutional investors at $2.50 per share in a registered direct offering expected to generate net proceeds of approximately $4.5 million. Closing is expected on February 2, 2017, the company said, and proceeds will be used to pay indebtedness … [Read more...] about Pulmatrix announces $5 million registered direct offering
Symbicort gets FDA approval for pediatric use
The FDA has approved the Symbicort budesonide/formoterol fumarate 80/4.5 μg MDI for the treatment of asthma in patients aged 6-12, AstraZeneca has announced. The company previously announced that it had received pediatric exclusivity for the product. Symbicort inhalation aerosol has been approved in the US for the treatment of asthma in patients 12 and up since … [Read more...] about Symbicort gets FDA approval for pediatric use